CS Paper Radar

CircuitATLAS: Agentic reasoning over a systems neuroscience knowledge graph for target discovery in circuitopathies

Gabriel Ocana-Santero, Marko Tvrdic

cs.AI q-bio.QMq-bio.NC ·submitted 2026-10-07 08:19 UTC · v1

Abstract

Drug discovery for neurological disease has traditionally centered on the molecules altered by disease. But the molecules that cause pathology are not necessarily the best points from which to reverse it. Here, we ask which otherwise unaltered molecular control points can be engaged to restore pathological neural circuits toward functional states. We present CircuitATLAS, a provenance-grounded systems-neuroscience knowledge graph and agentic framework for target discovery in circuitopathies. It structures literature-derived relationships across diseases, phenotypes, electrophysiology, circuits, brain regions, cell types and molecular effectors, while deliberately excluding direct disease-gene and disease-protein edges to reduce shortcut reasoning. The graph contains 3.83 million nodes and 7.66 million edges, including 5.31 million LLM-extracted relations, and incorporates structured datasets such as the Human Cell Atlas and new multimodal in vivo measurements. We then introduce an agentic workflow that reasons from measurable disease phenotypes through their circuit and cellular substrates to molecular interventions, therapeutic feasibility and clinical constraints. Finally, we introduce a human-governed in vivo lab-in-the-loop linking hypothesis generation to experimental iteration. Within this framework an agent nominated ATP1A3, the neuronal alpha3 Na+/K+-ATPase, as a control point on cortical excitability; interneuron-restricted expression of ATP1A3 abolished the beta- and gamma-band response to a focal 4-aminopyridine challenge in vivo, and the validated target was then carried into a structure-guided small-molecule campaign terminating in a defined assay to resolve the direction of modulation. CircuitATLAS thus provides a framework for discovering therapeutics based not only on what is molecularly disrupted in disease, but on what can be controlled to restore circuit function.

Comment
22 pages, 5 figures, 4 tables

Closest papers

Nearest neighbours by meaning across the whole index.

DrugReason: Dynamic Multi-View Reasoning over Knowledge Graph and Language Evidence for Drug Repurposing

cs.LG cs.AI ·2026-09-06 ·Zijie Liu, Hongxuan Li, Zhen Tan, Jinhao Duan, Baixiang Huang +3 more
top venuecode/data similarity 0.68
Abstract · EMNLP 2026 Main Conference Code: https://github.com/jesseliu0913/DrugReason

Drug repurposing aims to identify new therapeutic uses for existing compounds and, compared with de novo drug discovery, offers a faster and more cost-effective path to clinical translation. However, the space of candidate drug-disease pairs is enormous and their underlying relationships often depend on complex multi-hop biological mechanisms, making it difficult to reliably predict which pairs represent true therapeutic relationships. Existing approaches tackle this from two directions: knowledge graph-based methods organize curated biomedical evidence into structured relational networks for grounded multi-hop reasoning, while LLM-based methods leverage pretrained knowledge to generate flexible mechanistic rationales. Yet neither is sufficient alone - KGs are confined to observed graph structure while LLMs lack factual grounding and risk hallucination. To address this gap, we propose DrugReason, a multi-view reasoning framework that integrates grounded KG reasoning with LLM-generated mechanistic inference for drug repurposing. DrugReason adaptively routes diverse reasoning paths to specialized experts conditioned on the query context, while a cross-expert distillation objective enables knowledge sharing without sacrificing expert specialization. Experiments on PharmaDB, DDInter, and DrugBank show that DrugReason improves average performance over strong single-view reasoning baselines and achieves competitive or superior results compared with graph-based alternatives, while providing interpretable routing-based predictions.

0.53

Entropy-Guided Reverse-Causal AI to Identify Upstream Bottleneck Genes for Alzheimer's Drug Discovery

cs.CE ·2026-10-06 ·Victor O. K. Li, Jacqueline C. K. Lam, Yang Han, Lawrence Y. L. Cheung
similarity 0.67
Abstract

Identifying upstream regulators that connect several disease processes to therapeutic interventions is a central objective in Alzheimer's disease drug discovery. We propose an entropy-guided reverse-causal framework that makes candidate bottleneck genes the organizing link between disease mechanisms, pathways, molecular targets and drugs. The methodology integrates five stages: an Alzheimer's-specific knowledge graph with language-model assistance and expert review; reverse tracing from drugs to candidate genes; entropy-guided prioritization; forward propagation to drugs and complementary combinations; and staged validation with evidence feedback. The novelty lies in integrating upstream bottleneck identification, entropy-guided prioritization and iterative therapeutic selection within a dynamic, bidirectional discovery architecture. We demonstrate its molecular tracing and gene-prioritization components in a computational feasibility study using DeepDrug2 and MSigDB pathway annotations. Tracing amlodipine, indapamide and atorvastatin through a network of 11,300 molecular and drug nodes identifies 46 routes to nine genes. EGFR is the leading candidate, supported by 26 routes from all three drugs; MME and MAF rank next. These results show how pharmacological starting points can identify shared candidate genes with defined molecular connections. The framework's scientific significance lies in connecting convergent disease mechanisms to systematic intervention selection, with preservation of cognition and independence as the translational objective.

0.10

Cross-species representation learning aligns mouse and human neural dynamics and tracks clinical drug efficacy

cs.LG q-bio.QMq-bio.NC ·2026-10-08 ·Marko Tvrdic, Justin Richmond Domingo, Jae Ann Buenaluz, Jydell Ashley Palomo Penollar, Edmayelle Villavicencio Alforja +2 more
similarity 0.62
Abstract · 33 pages, 5 figures; supplementary material included (2 supplementary figures, 3 supplementary tables)

Preclinical models poorly predict human drug efficacy, particularly in neurological disorders. Neural activity offers a uniquely rich source of translational information because it captures high-dimensional variation in nervous-system function that can be measured in both animals and humans. However, its high dimensionality makes it difficult to distinguish conserved disease-related features from variation arising from species, recording modality and experimental context. Here, we test whether shared neural dynamics can be identified directly from electrophysiology data by learning representations organized by biological state rather than species. We develop a dual-rule contrastive learning framework that aligns corresponding mouse and human states while preserving separation between distinct phenotypes. This framework recovered conserved sensory-response structure across species and, in epilepsy, resolved distinct relationships between three mouse models and heterogeneous human patient populations. When treated animals were projected into a frozen cross-species representation, drug-induced movement towards the human-aligned healthy state retrospectively tracked known clinical efficacy across ten model-drug combinations including a disease-specific detrimental effect. The framework also identified shared disease-associated neural dynamics between Fmr1-knockout mice and human 16p11.2 copy-number variant carriers despite differences in genetic aetiology and recording modality. Together, these findings show the potential of cross-species neural representation learning to map heterogeneous human disease onto experimentally tractable preclinical states and assess whether interventions restore human-relevant circuit function.

0.40

Interpretable and Steerable Molecular Graph Generation using Concept Bottlenecks

cs.LG ·2026-10-25 ·Sarabeshwar Balaji, Ritesh Kumar, Lav R. Varshney
published similarity 0.61
Abstract · Accepted at AI for Drug Discovery Workshop @ NeurIPS 2026. Additional experiments added

Deep graph generators (DGGs) largely lack interpretability, which is a significant limitation for one of their most crucial applications, drug discovery, where interpretable and transparent generation could provide greater control over the desirability of generated molecules, thereby reducing trial-and-error in candidate selection. Common approaches to interpretability, such as disentanglement, cannot guarantee that the learned representations are human-interpretable. To address this, we propose incorporating concept bottlenecks into DGGs, allowing users to interpret, debug, and steer the generation process. We show that this consistently improves distributional fidelity (lower FCD), with only modest, non-systematic effects on validity and uniqueness. We further explore Concept Controller, an optimization-based steering approach that has proven to be effective for steerable image generation. We evaluate our approach on a one-shot molecular graph generation framework, though the underlying ideas can be transferred to sequential graph generation as well.

0.20

VINCENT: Validated Interaction Network for Cross-drug Explanation of Therapeutics

cs.LG cs.AI ·2026-08-26 ·Fan-Sheng Chuang, Xuchen Li, Yujing Bian, Kaixiong Zhou
similarity 0.60
Abstract · 18 pages, 4 figures

Drug synergy prediction estimates whether two drugs produce a stronger joint effect than expected from their individual activities. For drug combination discovery, a single synergy score is often not enough: researchers also need to know which molecular regions jointly drive the prediction. We study motif-pair synergy explanation, which identifies pairs of chemically coherent regions, one from each drug, that jointly contribute to predicted synergy. Existing interpretable synergy models expose atom- or substructure-level signals, but their explanations are built into the predictor architecture, and none validates cross-drug region scores under repeated perturbations or feeds that evidence back to refine the explanation. A reliable motif-pair explanation should instead be chemically coherent, perturbation-stable, and aligned with predictor behavior. We introduce VINCENT (Validated Interaction Network for Cross-drug Explanation of Therapeutics), a post-training framework for a fixed interaction-aware synergy predictor. VINCENT extracts atom-pair evidence from attention and gradient signals, groups atoms into chemically coherent motifs, and validates candidate motif pairs through repeated local perturbations. The validated evidence is fed back to refine motif assignments, yielding explanations that satisfy these three criteria. On a 25-pair literature-annotated subset, VINCENT achieves a mean motif recall of 0.826 (95% CI: 0.78-0.87), compared with 0.49-0.66 for baselines. Across all 71 test pairs, its validated interaction scores yield a TP/TN separation of 3.36. These results show that closed-loop perturbation validation recovers literature-supported molecular regions more accurately than existing alternatives while producing cross-drug interaction scores that better reflect predictor behavior.

0.16

ColdDDI: Evaluating Knowledge Utilization in Cold-Start Drug-Drug Interaction Prediction

cs.LG cs.CL ·2026-10-04 ·Jiheng Liang, Chen Zhao, Di Wu, Chenyang Bu, Yunpeng Hong +2 more
publishedbenchmarkcode/data similarity 0.60
Abstract · Accepted at NeurIPS 2026 (poster). Code: https://github.com/0217ljh/ColdDDI-NeurIPS2026

Cold-start drug-drug interaction (DDI) prediction tests whether models can identify clinically significant interactions for drugs without training-time interaction history. Existing benchmarks mostly report aggregate edge-prediction scores, leaving a key evaluation question unanswered: when models receive molecular, textual, or knowledge-graph (KG) evidence, do they actually use the evidence that pharmacologically supports the interaction? We introduce ColdDDI, a reconstructible diagnostic benchmark built from DrugBank 5.1.13, with 1,900 approved small-molecule drugs and 565,731 positive DDI pairs. ColdDDI evaluates pairs with zero, one, or two unseen drugs. It also annotates each interaction by whether it changes drug exposure or drug effect, and by whether the biomedical knowledge graph contains shared enzymes, transporters, or targets that can plausibly mediate the interaction. These annotations separate evidence availability from predictive dependence. We evaluate eight conventional DDI methods and 13 LLMs; for open-weight LLMs, we test five prompt patterns and use masking, drug replacement, and channel-sensitivity metrics to probe knowledge utilization. ColdDDI exposes that, in the hardest split where both drugs are unseen, the main performance divide is mediator availability. A fine-tuned 1B LLM recovers 89-93% of interactions with a shared enzyme, transporter, or target, but only 40-62% without such a mediator. More importantly, KG-provided evidence is not always used; several KG-augmented baselines change little when the shared mediator is masked or disrupted, whereas fine-tuned LLMs respond strongly to this intervention. Thus, ColdDDI evaluates knowledge utilization rather than knowledge access alone, showing where cold-start DDI models rely on mechanistic evidence and where they fail despite receiving it. Code is available at https://github.com/0217ljh/ColdDDI-NeurIPS2026.

0.39

BiGSyn: A Bi-Level Heterogeneous Graph Contrastive Learning Framework for Interpretable Drug Synergy Prediction

cs.AI ·2026-11-16 ·Senquan Wang, Hui Fang, Haoran Nan, Xingwei Wang, Qiang He
publishedbenchmark similarity 0.59
Abstract · 2026 IEEE International Conference on Data Mining (ICDM 2026)

Drug combination therapy has become a mainstream of modern medicine, with the potential to enhance efficacy, reduce toxicity, and overcome drug resistance. However, identifying synergistic drug combinations remains challenging, as it requires modeling complex interactions across multiple biological scales---from atom-level molecular structures to entity-level relations in biological networks. Existing approaches typically model these levels in isolation, overlooking complementary signals and long-range dependencies. To address these limitations, we propose BiGSyn, a Bi-level heterogeneous Graph contrastive learning framework for drug Synergy prediction. Specifically, BiGSyn leverages heterogeneous graph transformers to extract high-order dependencies from molecular graphs and biological networks, and introduces a bi-level contrastive learning objective to bridge the cross-level semantic gap. Extensive experiments on two benchmark datasets show that BiGSyn consistently outperforms state-of-the-art baselines. Moreover, its attention mechanism highlights key molecular substructures and biological interactions driving synergy, providing interpretable insights.

0.19

The Tangled Web They Weave: Exploring Neural Representations with Directed Simplicial Complexes

cs.LG ·2026-10-31 ·Michael Bleher
published similarity 0.59
Abstract · 52 pages, 16 figures. Accepted at NeurReps 2026 (Symmetry and Geometry in Neural Representations)

Understanding how artificial neural networks (ANNs) represent and combine features internally is a central challenge in mechanistic interpretability. Existing neural circuit-discovery methods represent neuron interactions as pairwise edges in a graph. But distributed neural representations consist of large groups of neurons that are inherently linked by higher-order causal dependencies: suppressing a subgroup of neurons in concert may shift the activation of other neurons in the feature representation. We propose a method to construct filtered directed simplicial complexes (DSCs) that give a topological representation of such dependencies, built from the activation profiles of an ANN on a given set of inputs. Our approach treats ANNs as structural causal models and uses counterfactual ablations to test for causal links between groups of internal neurons within specific input contexts. As a proof of concept, we apply the approach to a pair of small multilayer perceptron (MLP) architectures in a synthetic two-dimensional quadrant classification task. In these examples, DSCs recover the designed feature pathways and coordinated class transitions, and the complexes of trained networks are higher-dimensional than those of their handcrafted references. As validation, we compare our method with graph-based circuit-discovery baselines and find that their 1-skeletons agree within the relations that a weight graph can represent. These results support DSCs as context-dependent descriptions of multi-neuron computation and may thus provide a novel, orthogonal framework to study the phenomenon of distributed feature representations and polysemanticity.

0.33